About Careers Internship MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

FDA Approval For Lucentis

by Medindia Content Team on July 6, 2006 at 12:13 PM
Font : A-A+

FDA Approval For Lucentis

The first drug proven to significantly improve the vision of elderly patients was approved by the FDA on Friday.

The drug, Lucentis, is to treat age-related macular degeneration in its wet form, where blood vessels behind the retina leak, worsening vision and often leading to blindness. 90 percent of the 1.4 million Americans, who have lost their vision due to this degeneration, are estimated to have the wet form of the disease.

Lucentis is manufactured by Genentech, Inc., a Biotechnology Company based in South San Francisco, California. None of the other Food and Drug Administration (FDA)-approved treatments has been shown to significantly reverse vision deterioration, like Lucentis does. Lucentis cost $1,950 per injection, and should be used monthly or bimonthly.

Advertisement

Lucentis and Avastin, another Genentech cancer drug, block the same protein believed to instigate blood vessel growth. Dr. Hal Barron, Genentech chief medical officer said, "We believe Lucentis is a much better choice. I really believe when treating patients, you have to look at the wealth of data supporting its use and the quality of that data."

The FDA has not granted sanction for Avastin to be used in treating macular degeneration.

The National Eye Institute, part of the National Institutes of Health, has received an outside proposal to conduct a comparative study on Avastin and Lucentis in treating AMD.
Advertisement

The anticipated cost of Lucentis may limit its usage, while Avastin is far cheaper.

Neither drug is a complete cure for age-related macular degeneration.

The most commonly reported side- effects of Lucentis include conjunctival hemorrhage, eye pain, floaters, increased eye pressure and inflammation.

Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Anemia among Indian Women and Children Remains a Cause of Concern- National Family Health Survey-5
H1N1 Influenza Prevention in Children: What Parents Need to Know
Dietary Factors Responsible for Dihydrotestosterone (DHT) Production and Hair Loss
View all
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

Most Popular on Medindia

Selfie Addiction Calculator Sinopril (2mg) (Lacidipine) Turmeric Powder - Health Benefits, Uses & Side Effects Indian Medical Journals Daily Calorie Requirements Pregnancy Confirmation Calculator Nutam (400mg) (Piracetam) The Essence of Yoga A-Z Drug Brands in India How to Reduce School Bag Weight - Simple Tips
This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use
×

FDA Approval For Lucentis Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests